Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
WEBDec 10, 2020 · In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days...
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
WEBDec 30, 2020 · The Coronavirus Efficacy (COVE) phase 3 trial was launched in late July 2020 to assess the safety and efficacy of the mRNA-1273 vaccine in preventing SARS-CoV-2 infection. An independent data...
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine ...
WEBNov 18, 2020 · Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group. Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults ...
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
WEBSep 29, 2021 · In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with...
U.S. clinical trial results show Novavax vaccine is safe and …
WEBJun 14, 2021 · Results from a Phase 3 clinical trial enrolling 29,960 adult volunteers in the United States and Mexico show that the investigational vaccine known as NVX-CoV2373 demonstrated 90.4% efficacy in preventing symptomatic COVID-19 disease.
About Our Landmark Trial - Pfizer
WEBThe Phase 3 clinical trial was designed to determine if the Pfizer-BioNTech COVID-19 vaccine is safe and effective in preventing COVID-19 disease. This trial began July 27, 2020 and completed enrollment of 46,331 participants in January 2021.
ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 …
WEBJul 23, 2024 · The phase II/III randomized controlled trial (RCT) for the Pfizer-BioNTech COVID-19 vaccine demonstrated efficacy of the 2-dose regimen up to 6 months after vaccination. 1,2 The overall efficacy* against symptomatic, laboratory-confirmed COVID-19 § was 91.1% (95% Confidence Interval [CI]: 88.8%, 93.1%). Similar efficacy was observed in ...
ACIP Evidence to Recommendations for Use of Novavax COVID-19 Vaccine ...
WEBJul 27, 2022 · The clinical trial for the Novavax COVID-19 vaccine demonstrated high efficacy of the 2-dose regimen against symptomatic, laboratory-confirmed COVID-19 during a time of Alpha variant predominance. 1,2 The overall efficacy was 89.6% (95% Confidence Interval [CI]: 82.4%, 93.8%). Efficacy >75% was observed across age, race, ethnicity, and …
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High …
WEBSep 22, 2021 · First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain. In trial with more than 10,000 participants 16 years of age and older, COVID-19 booster was found to have a favorable safety profile.
ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine ...
WEBDec 20, 2020 · The clinical trial for the Moderna COVID-19 vaccine demonstrated very high efficacy of the 2-dose regimen against symptomatic, laboratory-confirmed COVID-19. 1,2 The overall efficacy* was 94.1% (95% Confidence Interval [CI]: 89.3%, 96.8%). Consistent high efficacy (≥86%) was observed across …